Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Harold Smith
Oyagen, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
University of Rochester
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The OyaGen statement of work is dependent upon the results from Dr. Smith's University lab, thus Dr. Smith's financial interest in OyaGen would reasonably appear to be affected by his University research.
Identification of Antagonists of the Molecular Chaperone Function of CBF beta
The proposal entitled Identification of Antagonists of the Molecular Chaperone Function of CBF? has been written in response to the Program Announcement PA-10-213 entitled Development of Assays for High-Throughput Screening for Use in Probe and Pre-therapeutic Discovery (R01). The significance and ultimate goal of this proposal is to develop, optimize and validate a novel live cell assay for the molecular interaction of the cellular transcription factor CBF? and the HIV Vif protein. This assay will be appropriate to screen chemical libraries for novel molecular probes. Vif binds to the host defense factor APOBEC3G (A3G) in order to induce A3G degradation, but Vif is unstable in cells without the molecular chaperone function of CBF?. Antagonists of CBF? binding to Vif are predicted to permit the destabilization of Vif and thereby enable A3G to inhibit HIV replication. Little is know of the chaperone function of CBF?, therefore this study will satisfy an unmet need for target-biased molecular probes that bind to either CBF? or Vif and only antagonize this interaction while not interfering with the transcription cofactor function of CBF?. It goes without saying that molecular probes may not only serve a basic research function but may have value in future therapeutic development studies.
Filed on July 17, 2015.
Tell us what you know about Harold Smith's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Harold Smith filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Harold Charles Smith | Oyagen, Inc. | Conflict of Interest | University of Rochester | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.